Gyberg Viveca, De Bacquer Dirk, De Backer Guy, Jennings Catriona, Kotseva Kornelia, Mellbin Linda, Schnell Oliver, Tuomilehto Jaakko, Wood David, Rydén Lars, Amouyel Philippe, Bruthans Jan, Conde Almudena Castro, Cifkova Renata, Deckers Jaap W, De Sutter Johan, Dilic Mirza, Dolzhenko Maryna, Erglis Andrejs, Fras Zlatko, Gaita Dan, Gotcheva Nina, Goudevenos John, Heuschmann Peter, Laucevicius Aleksandras, Lehto Seppo, Lovic Dragan, Miličić Davor, Moore David, Nicolaides Evagoras, Oganov Raphael, Pająk Andrzej, Pogosova Nana, Reiner Zeljko, Stagmo Martin, Störk Stefan, Tokgözoğlu Lale, Vulic Dusko
Cardiology Unit, Department of Medicine, Karolinska Institutet, Karolinska University Hospital Solna, 171 76, Stockholm, Sweden.
Centre for Family Medicine, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Huddinge, Sweden.
Cardiovasc Diabetol. 2015 Oct 1;14:133. doi: 10.1186/s12933-015-0296-y.
In order to influence every day clinical practice professional organisations issue management guidelines. Cross-sectional surveys are used to evaluate the implementation of such guidelines. The present survey investigated screening for glucose perturbations in people with coronary artery disease and compared patients with known and newly detected type 2 diabetes with those without diabetes in terms of their life-style and pharmacological risk factor management in relation to contemporary European guidelines.
A total of 6187 patients (18-80 years) with coronary artery disease and known glycaemic status based on a self reported history of diabetes (previously known diabetes) or the results of an oral glucose tolerance test and HbA1c (no diabetes or newly diagnosed diabetes) were investigated in EUROASPIRE IV including patients in 24 European countries 2012-2013. The patients were interviewed and investigated in order to enable a comparison between their actual risk factor control with that recommended in current European management guidelines and the outcome in previously conducted surveys.
A total of 2846 (46%) patients had no diabetes, 1158 (19%) newly diagnosed diabetes and 2183 (35%) previously known diabetes. The combined use of all four cardioprotective drugs in these groups was 53, 55 and 60%, respectively. A blood pressure target of <140/90 mmHg was achieved in 68, 61, 54% and a LDL-cholesterol target of <1.8 mmol/L in 16, 18 and 28%. Patients with newly diagnosed and previously known diabetes reached an HbA1c <7.0% (53 mmol/mol) in 95 and 53% and 11% of those with previously known diabetes had an HbA1c >9.0% (>75 mmol/mol). Of the patients with diabetes 69% reported on low physical activity. The proportion of patients participating in cardiac rehabilitation programmes was low (≈40 %) and only 27% of those with diabetes had attended diabetes schools. Compared with data from previous surveys the use of cardioprotective drugs had increased and more patients were achieving the risk factor treatment targets.
Despite advances in patient management there is further potential to improve both the detection and management of patients with diabetes and coronary artery disease.
为影响日常临床实践,专业组织发布管理指南。横断面调查用于评估此类指南的实施情况。本调查研究了冠状动脉疾病患者的血糖紊乱筛查,并根据当代欧洲指南,比较了已知和新诊断的2型糖尿病患者与无糖尿病患者在生活方式和药物危险因素管理方面的情况。
在2012 - 2013年欧洲动脉粥样硬化调查IV(EUROASPIRE IV)中,对来自24个欧洲国家的6187例年龄在18 - 80岁之间、根据自我报告的糖尿病病史(既往已知糖尿病)或口服葡萄糖耐量试验及糖化血红蛋白(HbA1c)结果(无糖尿病或新诊断糖尿病)确定血糖状态的冠状动脉疾病患者进行了调查。对患者进行访谈和调查,以便将他们实际的危险因素控制情况与当前欧洲管理指南中推荐的情况以及之前调查的结果进行比较。
共有2846例(46%)患者无糖尿病,1158例(19%)新诊断糖尿病,2183例(35%)既往已知糖尿病。这三组中四种心脏保护药物联合使用的比例分别为53%、55%和60%。血压目标<140/90 mmHg的实现率分别为68%、61%、54%,低密度脂蛋白胆固醇目标<1.8 mmol/L的实现率分别为16%、18%和28%。新诊断和既往已知糖尿病患者的糖化血红蛋白(HbA1c)<7.0%(53 mmol/mol)的比例分别为95%和53%,既往已知糖尿病患者中有11%的糖化血红蛋白>9.0%(>75 mmol/mol)。糖尿病患者中有69%报告身体活动量低。参与心脏康复计划的患者比例较低(约40%),糖尿病患者中只有27%参加过糖尿病学校。与之前调查的数据相比,心脏保护药物的使用有所增加,更多患者达到了危险因素治疗目标。
尽管在患者管理方面取得了进展,但在改善糖尿病和冠状动脉疾病患者的检测与管理方面仍有进一步的潜力。